110 related articles for article (PubMed ID: 27009215)
1. Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth.
Choi SS; Chi BH; Chang IH; Kim KD; Lee SR; Kim SU; Lee HJ
Mol Cancer Ther; 2016 Jun; 15(6):1201-7. PubMed ID: 27009215
[TBL] [Abstract][Full Text] [Related]
2. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
3. Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice.
Lee HJ; Doo SW; Kim DH; Cha YJ; Kim JH; Song YS; Kim SU
Cancer Lett; 2013 Jul; 335(1):58-65. PubMed ID: 23391716
[TBL] [Abstract][Full Text] [Related]
4. Human neural stem cell tropism to metastatic breast cancer.
Zhao D; Najbauer J; Annala AJ; Garcia E; Metz MZ; Gutova M; Polewski MD; Gilchrist M; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2012 Feb; 30(2):314-25. PubMed ID: 22084033
[TBL] [Abstract][Full Text] [Related]
5. Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
Yi BR; Hwang KA; Kim YB; Kim SU; Choi KC
Int J Mol Sci; 2012 Sep; 13(10):12519-32. PubMed ID: 23202910
[TBL] [Abstract][Full Text] [Related]
6. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Gutova M; Shackleford GM; Khankaldyyan V; Herrmann KA; Shi XH; Mittelholtz K; Abramyants Y; Blanchard MS; Kim SU; Annala AJ; Najbauer J; Synold TW; D'Apuzzo M; Barish ME; Moats RA; Aboody KS
Gene Ther; 2013 Feb; 20(2):143-50. PubMed ID: 22402322
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase.
Lim SH; Choi SA; Lee JY; Wang KC; Phi JH; Lee DH; Song SH; Song JH; Jin X; Kim H; Lee HJ; Lim I; Kim SU; Kim SK
Cancer Gene Ther; 2011 Nov; 18(11):817-24. PubMed ID: 21869821
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
Danks MK; Yoon KJ; Bush RA; Remack JS; Wierdl M; Tsurkan L; Kim SU; Garcia E; Metz MZ; Najbauer J; Potter PM; Aboody KS
Cancer Res; 2007 Jan; 67(1):22-5. PubMed ID: 17210679
[TBL] [Abstract][Full Text] [Related]
9. Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice.
Yi BR; Kim SU; Choi KC
Oncotarget; 2014 Dec; 5(24):12835-48. PubMed ID: 25544747
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.
Gutova M; Najbauer J; Chen MY; Potter PM; Kim SU; Aboody KS
Curr Stem Cell Res Ther; 2010 Sep; 5(3):273-6. PubMed ID: 19951251
[TBL] [Abstract][Full Text] [Related]
11. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
[TBL] [Abstract][Full Text] [Related]
12. Genetically-engineered human neural stem cells with rabbit carboxyl esterase can target CNS lymphoma.
Kang W; Jin J; Yang H; Seol HJ; Kim KH; Lee JI; Kim SU; Joo KM; Nam DH
Anticancer Res; 2013 Dec; 33(12):5335-42. PubMed ID: 24324067
[TBL] [Abstract][Full Text] [Related]
13. Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
Kim KY; Kim SU; Leung PC; Jeung EB; Choi KC
Cancer Sci; 2010 Apr; 101(4):955-62. PubMed ID: 20704576
[TBL] [Abstract][Full Text] [Related]
14. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Oosterhoff D; Witlox MA; van Beusechem VW; Haisma HJ; Schaap GR; Bras J; Kruyt FA; Molenaar B; Boven E; Wuisman PI; Pinedo HM; Gerritsen WR
Mol Cancer Ther; 2003 Aug; 2(8):765-71. PubMed ID: 12939466
[TBL] [Abstract][Full Text] [Related]
15. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific gene therapy for pancreatic cancer using human neural stem cells encoding carboxylesterase.
Choi SS; Yoon K; Choi SA; Yoon SB; Kim SU; Lee HJ
Oncotarget; 2016 Nov; 7(46):75319-75327. PubMed ID: 27659534
[TBL] [Abstract][Full Text] [Related]
17. Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models.
Yi BR; Hwang KA; Aboody KS; Jeung EB; Kim SU; Choi KC
Stem Cell Res; 2014 Jan; 12(1):36-48. PubMed ID: 24141111
[TBL] [Abstract][Full Text] [Related]
18. Carboxylesterase-overexpressing hTERT-immortalized human adipose stem cells in prostate tumor growth inhibition by irinotecan.
Kim JH; Oh E; Song ES; Yun CW; Lee SH; Song YS
J Cancer Res Ther; 2023 Oct; 19(7):1731-1742. PubMed ID: 38376272
[TBL] [Abstract][Full Text] [Related]
19. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
[TBL] [Abstract][Full Text] [Related]
20. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
